Advertisement


Nicholas David James, MD, PhD, and Celestia S. Higano, MD, on Results From the STAMPEDE Trial on Hormone-Naive Prostate Cancer

2015 ASCO Annual Meeting

Advertisement

Celestia S. Higano, MD, of the University of Washington, and Nicholas David James, MD, PhD, of Warwick Medical School, discuss data showing improvements in survival from adding docetaxel in men starting long-term hormone therapy for the first time (Abstract 5001).



Related Videos

Sarcoma

Patrick Schöffski, MD, on Eribulin for Soft-Tissue Sarcomas

Patrick Schöffski, MD, of the University Hospital Leuven, discusses a phase III study in which he and his colleagues found, for the first time in soft-tissue sarcomas, a significant overall survival benefit of a single agent compared to a standard treatment (Abstract LBA10502).

Cost of Care

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.

Lung Cancer

Luis G. Paz-Ares, MD, PhD, Summarizes Results of the CheckMate 057 Trial on Nonsquamous Cell NSCLC

Luis G. Paz-Ares, MD, PhD, of the Hospital Universitario Doce De Octubre, discusses the superior overall survival in patients taking nivolumab vs docetaxel in advanced nonsquamous NSCLC (Abstract LBA109).

Breast Cancer

Nicholas C. Turner, MD, PhD, and Clifford A. Hudis, MD, on Results of the PALOMA3 Study on Hormone Receptor–Positive, HER2 Negative Metastatic Breast Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discuss fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed on prior endocrine therapy (Abstract LBA502).

Hematologic Malignancies

Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

Advertisement

Advertisement




Advertisement